Welcome to our dedicated page for Dexcom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on Dexcom stock.
DexCom, Inc. reports news about its continuous glucose monitoring and glucose biosensing business for people with diabetes. Company updates commonly cover Dexcom G7 clinical evidence, product roadmap activity, U.S. and international revenue trends, margins, guidance, and presentations at diabetes technology and healthcare investor conferences.
Dexcom news also includes corporate governance developments, board appointments, management presentations, and long-term strategy discussions tied to its CGM portfolio, global commercialization, and innovation in metabolic health.
Dexcom (NASDAQ:DXCM) reported results from the CONNECT randomized controlled trial in adults with Type 2 diabetes not using insulin. Using Dexcom G7 CGM led to a 1.6% average A1C reduction (0.9% greater than control), improved time-in-range, lower hyperglycemia, and higher treatment satisfaction over 26 weeks.
Dexcom (NASDAQ:DXCM) highlighted new clinical, product and strategic initiatives at ADA 2026 to broaden continuous glucose monitoring (CGM) use, especially for people with Type 2 diabetes not on insulin.
Key updates include CONNECT trial data, an FDA-cleared reimagined Stelo app, and the planned acquisition of Nutrisense to add personalized nutrition coaching.
Dexcom (NASDAQ:DXCM) released its first Customer Advisory Council Report, sharing feedback from people with diabetes, caregivers, clinicians and advocates, and outlining six specific commitments to enhance product performance and user experience.
Dexcom is making the Council permanent and will provide regular 2026 updates on progress against these commitments.
Summary not available.
Dexcom (Nasdaq: DXCM) announced Dexcom Flex, a new continuous glucose monitoring (CGM) system for adults with Type 2 diabetes who are not on intensive insulin therapy. The system will launch in Germany soon.
Dexcom Flex offers 24/7 glucose readings on smartphones, smartwatches or a receiver without routine fingerpricks, plus optional low alerts, food and activity logging, and personalised insights. It is aimed at people using basal insulin, oral medications or GLP‑1 receptor agonists and is intended to broaden CGM access and support earlier, more tailored Type 2 diabetes management. Dexcom cites research indicating CGM use in Type 2 diabetes may be associated with fewer hospitalisations, reduced long-term complications and improved confidence in managing glucose levels.
Dexcom (NASDAQ:DXCM) announced governance changes ahead of its 2026 Investor Day. The company plans to add two new independent directors with MedTech leadership or lean operations experience, identified in collaboration with Elliott Investment Management.
Dexcom will also rename its Board Technology Committee as the Operations and Innovation Committee, expanding its mandate to cover operations, quality and the technical roadmap. With the planned appointments, Dexcom will have added six new independent directors since early 2023.
Dexcom (NASDAQ:DXCM) will host an Investor Day on May 14, 2026 from 1:15 PM to ~3:30 PM PDT (4:15 PM–6:30 PM EDT).
The program will feature management presentations on market opportunities, business strategy, innovation efforts, and the company’s long-term financial outlook. A live webcast and archived replay will be available on the investor relations website.
Dexcom (Nasdaq: DXCM) reported Q1 2026 revenue of $1.192B, up 15% year‑over‑year (12% organic). GAAP operating income was $255.3M (21.4% of revenue); non‑GAAP operating income was $264.4M (22.2%). GAAP net income was $199.5M or $0.51 diluted EPS. Cash and marketable securities totaled $2.42B.
Dexcom expanded G7 15 Day CGM U.S. launch, added Smart Meal Logging to Stelo, presented clinical data including one‑year A1C improvement for G7 in type 2 diabetes, and raised 2026 targets for non‑GAAP operating margin and adjusted EBITDA margin while reiterating revenue guidance of $5.16–$5.25B.
Dexcom (NASDAQ:DXCM) will release first quarter 2026 financial results after market close on April 30, 2026.
Management will host a concurrent conference call and webcast at 4:30 p.m. Eastern Time the same day; the webcast link will be available and archived on the company's investor relations website.
Dexcom (NASDAQ:DXCM) will present clinical and real-world data at ATTD 2026 (March 11-14) showing Dexcom G7 use in non-insulin Type 2 diabetes is associated with improved A1C and weight management. Presentations also report fewer DKA-related hospitalizations in Type 1 diabetes and positive feasibility results for Dexcom Smart Basal. ATTD sessions will detail near-term product features (G7, G7 15 Day, Dexcom ONE+, Stelo, Clarity, next-gen sensor) and rollout of Dexcom Academy HCP education across multiple countries in 2026.